Creo Medical Group plc announced that its latest device, Speedboat UltraSlim, has now been successfully used in the USA. The limited market release of the Speedboat UltraSlim in the USA has resulted in the device being successfully used in multiple clinical applications. The first was a Speedboat Submucosal Dissection (SSD) in the colon for a precancerous lesion, followed by a precancerous resection in the oesophagus.

Additional successful indications were Upper Oesophageal Peroral Endoscopic Myotomy and Zenkers Diverticulum, treating swallowing disorders and gastroparesis. These procedures come shortly after the Company announced that it had obtained 510(k) clearance from the US Food & Drug Administration for Speedboat UltraSlim in November 2023 and follows the first UK case earlier this week. Speedboat UltraSlim is the third device in Creo's Speedboat family of products, and is targeting the therapeutic treatment of disease in the GI tract (including cancer of the Bowel, Stomach and Oesophagus) as well as surgical procedures to deal with abnormalities resulting in swallowing disorders and, in some cases, gastric reflux.

This latest generation Speedboat has broad application in the GI tract due to a smaller configuration, ensuring compatibility with a wide range of colonoscopes and gastroscopes. Powered by Creo's CROMA advanced energy platform, Speedboat UltraSlim delivers fluid as well as advanced bipolar radiofrequency energy for controlled cutting and high frequency microwave energy for controlled coagulation of tissue in the GI tract. The device is the culmination of a long programme of work to further miniaturise Creo's technology, and is compatible with the working channel of all commercially available endoscopes accessing the vast majority of GI endoscopic procedures.